Speaking to CNBC-TV18 Pranav Amin, Managing Director of Alembic Pharmaceuticals, said that good Q1 numbers were led by international business. Sales of its anti-psychotic drug Abilify was one of the reasons the company saw higher sales, he said.
There is growing harmonisation between leading regulators across the world and WHO is taking note of the observations made by US FDA on pharma companies everywhere, says Surajit Pal, pharma analyst at Prabhudas Lilladher.
In an interview with CNBC-TV18‘s Ekta Batra and Reema Tendulkar, Pranav Amin, Director & President- International Business, Alembic Pharmaceuticals, discussed the company‘s quarterly earnings.
Once this deal is concluded, the company will be renamed as Alembic Mami SPA.
The growth for the international generics, however, remain muted at about 9 percent due to higher base last year.
In an interview to CNBC-TV18, Amin adds that the company, despite the drug pricing policy, will grow at 15 percent.
Ranbaxy shares declined a further 2 percent on Wednesday morning after a media report said a prominent hospital in Mumbai had advised doctors to stop using the pharma company's drugs.
Alembic Pharma is hopeful to increase operating margin by 100-120 basis points in current financial year on the back of strong growth in international and domestic generic business.
Alembic Pharma has announced its third quarter results. Pranav Amin, director of Alembic Pharma says, the revenues have gone up 15%, YoY. He further says, the company so far has filed 41 abbreviated new drug applications (ANDAs). “Over the next couple of years, we should see quite a bit of growth coming in international generic,” he adds.